Abstract
Introduction Acute ST elevation myocardial infarction (STEMI) is one frequent and serious presentation of acute coronary syndrome. The STOP SCA+ study aimed to identify factors associated with negative outcomes one year after STEMI, particularly the impact of rehabilitation care and compliance.
Methods Patients>18 years old hospitalized for STEMI management in five interventional cardiac centers in one French region (2.5 million inhabitants), between 2014 and 2018, were included. After a probabilistic matching with the National Health Insurance database (SNDS, 96% matching), compliance for cardiac tri-therapy was studied: aspirin, P2Y12 inhibitor statin. Factors associated with poor outcomes (ischemic complications, death) were analyzed using Cox modelling and those for the compliance by logistic regression.
Results 3,768 patients were included, with 84% of primary percutaneous coronary intervention. At one year, 3,362 were prescribed a tri-therapy (89.2%) among whom 53% were compliant; 2,478 patients went to cardiac rehabilitation (65.8%). Death occurred in 130 patients and/or ischemic complication in 194 (total poor outcome 8.0%). Compliance was not associated with complications over the year (HR 1.16 [0.86-1.57]), while the absence of cardiac rehabilitation was (2.31 [1.73-3.08]). Additionally, cardiac rehabilitation was associated with compliance (OR 1.55 [1.34-1.79]).
Discussion STEMI clinical evolution at one year is mainly favorable. Pejorative outcomes were scarce, and appeared to be related to patients’ characteristics, initial STEMI presentation, and no access to rehabilitation. Compliance part in patient health outcome will need further modelling to accurately study its impact. Matching clinical and medico-administrative databases proved to be relevant for assessing outcomes at a large scale.
What is already known
Although the compliance with a cardiac treatment and cardiac rehabilitation immediately after a myocardial infarction are key factors for improving the prognosis, less is known about compliance maintenance at one year.
What this study adds
At one year, few poor outcomes occurred and were not associated with compliance to the cardiac tri-therapy, while they were associated with the absence of cardiac rehabilitation.
Matching two complementary clinical and medico-administrative databases proved to be reliable for assessing outcomes on a large scale (4,000 individuals over 5 years).
Competing Interest Statement
D Angoulvant reports speaker and/or consulting fees from Amarin, Amgen, Alnylam, AstraZeneca, Bayer, Boehringer, Bristol-Myers-Squibb, Bouchara-Recordati, Novartis, NovoNordisk, Organon, Pfizer, Sanofi, Servier, and Vifor.
Funding Statement
The CRAC registry is supported by unrestricted grants from the Centre-Val de Loire regional Health Agency (Agence Régionale de Santé Centre-Val de Loire), a public organism, and several private companies: Astra-Zeneca, Medtronic, Boston scientific, Abbot, Biosensor, Terumo, Biotronik, Lilly Daichii sankyo, Hexacath and Braun. Sponsors were not involved in the design, study progression, collection, management, data analyses and interpretations, neither in the preparation, review or approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Commission Nationale de l'Informatique et des Libertés (CNIL), decision DR-2021-025 (January 28th, 2021)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
pierre.marcollet{at}ch-bourges.fr
s.chassaing{at}ciic.fr
mariedecomis{at}hotmail.fr
julien.bezin{at}u-bordeaux.fr
Data Availability
The data underlying this article cannot be shared publicly due to privacy and legal reasons, according to the decision from the French Data Protection Board (Commission Nationale de l'Informatique et des Libertés, CNIL), decision DR-2021-025 (January 28th, 2021).
